Is the capillary electrophoresis kit for mRNA vaccine capping efficiency detection in stock?

For domestic substitution, a method comparison must be performed; do not simply release based on the supplier's provided documentation. It is recommended to first use samples with known capping rates and integrity ranges across at least three batches: for specificity, examine the resolution of uncapped/capped products; for precision, evaluate repeat injections within the same batch and interday reproducibility; for accuracy, use spike recovery or cross-comparison with mass spectrometry/imported reagents. The baseline integration method for calculating capping rate must be fixed; otherwise, changes in peak area after switching reagents can be misleading. If the supplier has complete method validation documentation, it can be requested, but it is best to reproduce the key items in-house, especially the resolution capability for low-capping-rate samples. Incorporate inter-batch reagent variability into the validation; do not validate only a single batch.

When screening domestic suppliers, it is recommended to create a comparison table: whether the item is in stock/specific lead time, whether it is compatible with your CE platform, whether capping rate application protocols are provided, whether methodology validation data are available, whether small-pack trial samples are offered, and whether batch pricing for the same specification follows a consistent basis. Focus on asking about reagent storage conditions and post-opening shelf life, as well as whether technical engineers can provide remote or on-site troubleshooting. Imported reagents have long lead times, but you can ask domestic distributors whether they have bonded warehouses or can source from peers; some reagents can be repackaged in smaller quantities, but confirm that the cold chain remains intact. Do not rely solely on one company's claim of "replaceability." It is best to obtain same-batch samples and run parallel tests with 2-3 suppliers, check whether the CE peak profiles are comparable, and then make a decision based on supply stability.

The budget of 80 RMB per run must be calculated on a full-cost basis, not just the single-run separation gel consumption. Domestic reagents may approach this range at certain throughput levels, but it is advisable to factor in capillary wash solution, internal standards, standard re-testing, failed reruns, and capillary breakage. Given that you process 20–30 samples per day, you can compare prices from 2–3 domestic suppliers based on quarterly or annual usage, and ask clearly whether there are full-case or bulk discounts, and whether the unopened shelf life covers your usage. Do not determine cost based only on small-package purchases; wait until usage is stable before calculating the true per-run cost. If the budget is tight, you can first perform mixed-injection prescreening and then re-test abnormal samples individually, reducing overall reagent consumption.

For in-stock options, focus on domestic manufacturers that make consumables for nucleic acid capillary electrophoresis or mRNA quality control reagents, such as those producing CE-SDS and fragment analysis reagents. Ask them directly whether they have small-pack trial sizes of premixed solutions/separation gels for capping rate detection. Before ordering, confirm three things: whether they are compatible with your existing instrument model, whether they provide an application note for capping rate detection, and whether the shipment is ready-to-use reagent or requires you to prepare the mother solution yourself. Don't just look at "in stock" — have them send the COA for the most recent batch and the supporting standard/internal standard scheme first. It's best to evaluate the reagent and the capillary together to avoid consumables being out of sync and causing a bottleneck.